Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?

VanEck Biotech ETF (BBH) returned 45.03% over the past year versus 25.99% for Fidelity MSCI Health Care Index ETF (FHLC), but BBH experienced a much deeper five-year maximum drawdown of 39.9% versus 17.7%. FHLC offers broader exposure to roughly 350 healthcare companies, a lower 0.08% expense ratio versus BBH's 0.35%, and $3.5B in assets under management compared with BBH's $469.4M. The comparison favors FHLC for lower-cost, diversified and lower-volatility healthcare exposure, while BBH suits investors seeking concentrated biotech exposure and willing to accept greater risk.

Analysis

This is not a fundamental catalyst for the underlying healthcare equities; it is primarily a portfolio-construction comparison and should not independently move AMGN, GILD, VRTX, ABBV, JNJ, or LLY. The relevant market mechanism is that a broad healthcare allocation dilutes single-drug, clinical-trial, and patent-expiry risk with managed care, providers, devices, and tools exposure, while a biotech sleeve concentrates idiosyncratic regulatory and pipeline beta. The fee differential is economically immaterial over a 1-3 month trading horizon; it matters only for multi-year strategic allocations.

The more useful relative-value question is whether recent biotech strength reflects a durable easing in policy/rate headwinds or a narrow large-cap biotech rerating. BBH's concentration means AMGN, GILD, and VRTX can drive returns disproportionately, but it also leaves investors exposed to patent-cliff execution, M&A premium compression, and drug-pricing-policy surprises. Broad healthcare offers a better defensive expression if growth decelerates, but FHLC's large LLY/ABBV/JNJ exposure introduces valuation and product-cycle concentration that the headline diversification statistic understates.

Contrarian view: the recent performance gap should not be extrapolated as evidence that concentrated biotech is structurally superior. Large-cap biotech can outperform sharply during an M&A or rate-cut narrative, then lag once acquisition premiums are realized and pipeline catalysts become stock-specific. There is no immediate trade from this article; monitor relative performance of XBI versus XLV/FHLC and biotech deal activity before adding cyclical biotech beta.

Key Decisions for Investors

• No event-driven position based on this article. Treat it as a strategic-allocation signal rather than a near-term catalyst for the named constituents.
• For a 6-18 month defensive healthcare allocation, prefer broad exposure via FHLC or XLV over concentrated biotech exposure; this reduces binary pipeline and patent-cliff risk while retaining LLY, ABBV, and JNJ participation.
• For a 1-3 month tactical biotech view, use a defined relative-value framework: long XBI versus short XLV only if XBI breaks above its prior relative high with accelerating announced biotech M&A. Falsify on a 5-7% reversal in XBI/XLV relative performance or a material decline in deal announcements.
• Avoid chasing AMGN, GILD, and VRTX solely on sector momentum. Add only around company-specific catalysts with verified revenue/guidance upside; reassess if consensus EPS estimates fail to rise following positive pipeline or regulatory developments.